|COi\TEi\TS|Page|
|---|---|
|LegalandAdministration||
|Chairman'sSummary|2|
|Trustees'Report|3-11|
|IndependentAuditors'Report|12-14|
|StatementofFinancialActivities|15|
|Balance Sheet|16|
|StatementofCashFlows|17|
|NotestotheFinancialStatements|18-26|






|<br> **mmunot**<br>**U**<br>ChangingLivesThrough<br>-<br>**LEGAL AND ADMINISTRATION **|**rapy **<br> Research|
|---|---|
|**TRUSTEES **|HenryRichardGeersCotterellBtOBE(Chairman)|
||ReshmaAshrafMason|
||GuyEdmundSangster|
||JemmaFreeman|
||AlexanderJohns|
||SaffronGuy|
|**COMPANY SECRETARY **|ReshmaAshrafMason|
|**REGISTERED OFFICE **|BrydenJohnsonLimited|
||I-4KingsParade|
||LowerCoombeStreet|
||Croydon|
||`CRO `\AA|
|**DIRECTOR **|MarieDimond|
||Unit15|
||AbbevilleMews|
||88ClaphamParkRoad|
||London|
||SW47BX|
|**SECRET ARY TO TRUSTEES **|AbigailParry-Williams|
|**FINANCIAL ADVISOR **|DavidMcCormick|
|**AUDITORS **|BrydenJohnsonLimited|
||l-4KingsParade|
||LowerCoombeStreet|
||Croydon|
||`CRO `!AA|
|**SOLICJTORS **|Ashurst|
||BroadwalkHouse|
||5AppoldStreet|
||LondonEC2A 2HA|
|**PRl!\CIPAL BAl'\'KERS **|BarclaysBankpie|
||Kensington andChelsea|
||POBox4599|
||LondonSW31XE|
|**INVEST.VIENT MANAGERS **|CazenaveCapitalManagement|
||12Moorgate|
||London|
||EC2R6OA|
|**GOVERNING DOCUMENT**|TheMemorandumandArticlesofAssociationincorporated26 November|
||1999 asamendedbyspecialresolution dated30March:2000|





## 




## 

## 

## 

## 

## 




## 

## 




## 

## 




## 

## 

## 








## 

||I|**2023 **|**2022 **|
|---|---|---|---|
|**Total Income **||**£620,770 **|**£566,386 **|
|**Net (Deficit)/Gains including Investment Gains**||**£35,834**|**£(177, **I88)|
|**Net Assets **||**£1,432,748 **|**£1,396,914 **|
|**Unrestricted Funds **||£**1,08**I**,249 **|**£1,139,681 **|



## 














## 






## 

## 

## 

## 




## 

## 

## 




## 



|||**Un restricted **|**Restricted **|**Total **|**Total **|
|---|---|---|---|---|---|
|||**Funds **|**Funds **|**Funds **|**Funds **|
|||**2023**|**2023**|**2023**|**2022 **|
||**Notes **|£|£|£|£|
|**INCOME FROM: **||||||
|**Donations and legacies **||8-1,420|516,659|601.079|565,866|
|**Charitable activities **||||||
|Symposium||||||
|Investmentincome||19,691||19.691|520|
|**Total income **||104.111|516,659|620.770|566.386|
|**EXPENDITURE 0:--1: **||||||
|Raising funds||81,394||81.394|64.118|
|Charitableactivities||81,149|422,393|503.542|679.456|
|**Total expenditure **|2|162,543|422,393|584,936|743.574|
|**et income/ (expenditure) beforeinvestment**||||||
|**(losses) **||(58,432)|94.266|35,834|(I77,188)|
|Netgain/(losses)oninvestments|7|||||
|**Net movementin funds **||(58.432)|94.266|35,834|(177,188)|
|**Balance broughtforward **I**April 2022 **||1.139,681|257.233|1.396.91-1|1.57-1.102|
|**Balance carried forward 31 March 2023 **|11|1,081,249|351,499|1.432. 748|1.396.91-1|





## 

## 

|||**2023 **||**2022 **||
|---|---|---|---|---|---|
||**Note**|£|£|£|£|
|**FIXED ASSETS**||||||
|Tangibleassets|6||304||180|
|Investments|7||_l,060,520 _||1,192,739|
||||1,060,824||1,192,919|
|**CURRENT ASSETS **||||||
|Debtors|8|423,403||37,068||
|Cashatbankandinhand||22,429||453,773||
|||445,832||490,841||
|**CREDITORS: Amountsfalling **||||||
|**due withinone year **|9|(73,908)||(286,846)||
||||371,924||203,995|
|**NET ASSETS **|||1,432,748||1,396,914|
|Funds:||||||
|Unrestricted|10||1,081,249||1,139,681|
|Restricted|11||351,499||257,233|
||||1,432,748||1,396,914|






## 

## 

||**2023 **|**2022 **|
|---|---|---|
||£|£|
|**Cash from operating activities **|||
|Netcash(usedin)/by operatingactivities|(--i3l,005)|377.859|
|**Cashflows from investing activities **|||
|Purchaseoffixedassets|(340)||
|Cashwithdrawals (investments)|(150,000)||
|Purchaseofinvestments|||
|Investmentincomereceived|17,781|520|
||(132,599)|520|
|**Change incash and cash equivalents in the year **|**(563,564) **|**378,379 **|
|Cashandcash equivalents atthebeginning oftheyear|2.458.473|1.268.133|
|**Cash and cash equivalents at the end of the year **|**1,894,909 **|**1,646,512**|
|||======|
||**2023 **|**2022 **|
|**Net income/(expenditure) for the reporting period **|£|£|
|**(as per the statement of activities)**|35.834|(177.188)|
|Depreciationcharges|219|43,133|
|Cashwithdrawals(investments)|150,000||
|Dividends,interestandrent frominvestments|(17,781)|(520)|
|Increase/fDecrease)increditors|(212,939)|408,145|
|(Increase)/Decreaseindebtors|(386,338)|104.145|
||**(431,005) **|**377,859 **|
|**Analysisof change in net funds **|||
||**2023**|**2022 **|
||£|£|
|Cashat bank|22,429|453,773|
|Investmentsheldascash|1,060,520|1,192.739|
|**Total cash and cash equivalents **|**1,082,949**|**1,646,512 **|






## 

## 














|**2. **|**EXPENDITURE **|**2023**|**2022**|
|---|---|---|---|
|||£|£|
|**(a)**|**Raising funds**(allunrestricted)|||
||Fundraisingsalariesincludingnational insurance|94,231|81,422|
||Travel.subsistence andrelated expenses|186|123|
||Events.committeemeetingsetc.|1,225|731|
||Marketingandpublicrelations|5,752|1,842|
||PersonnelcostsallocatedtoCharitable&Support|(20,000)|(20,000)|
||lnvestrnentcharges|||
|||81,394|64,118|
|**(b)**|**Charitable activities: **|||
||ContributiontoresearchfacilityatStGeorge'sUniversityofLondon|||
||-Staffincludingrecruitment(restricted)|350.410|-152.1-Q|
||-Consumables(restricted)|59,675|84,703|
||Symposium|||
||Personnelcostsallocatedtocharitableexpenditure(restricted)|10,000|10,000|
||Conference,travelandsubsistence(restricted)|2,308|7,707|
||Equipment maintenance|12,388|11,948|
||Equipmentdepreciation||42,521|
|||434,781|609,021|
|**(c) **|**Support **(allunrestricted)|||
||Rent,rates.and utilities|22.239|19,938|
||Telephone,printing,postageandstationery|13.384|14.405|
||Insurance|3.543|2,979|
||Bank andinvestmentcharges|2.408|2,467|
||Professionalfees||3,619|
||Depreciation|219|612|
||Personnelcostsallocatedto administration|10,000|10,000|
||Governance-Otherprofessionalcosts|3,200|5,050|
||Governance-Accountancyandaudit|13,768|11,365|
|||68.761|70,435|
||Total|584,936|743,574|
|**3. **|**ST AH COSTS **|**2023**|**2022 **|
|||£|£|
||Wages andsalaries|82,928|75,130|
||SocialSecurityCosts|4.597|3,927|
||Pensioncontributions|6.588|2,254|
|||94,113|81,311|





## 

## 

|**4. **|**:\ET MOVEMENT IN FUNDS **|**2023**|**2022 **|
|---|---|---|---|
|||£|£|
||Thisis statedaftercharging:|||
||Depreciation|219|43.135|
||Auditors·remuneration|8.400|8.400|



## 

|**5. **|**TRUSTEES' REMUNERATION AND REIMBURSED EXPENSES**|**TRUSTEES' REMUNERATION AND REIMBURSED EXPENSES**|**TRUSTEES' REMUNERATION AND REIMBURSED EXPENSES**|||
|---|---|---|---|---|---|
||None ofthe Trusteesreceivedanyremuneration.reimbursed expensestotalled £Nil(2022:£Nil)|||duringtheyear.||
||TheTrustees are coveredunderaTrusteesliabilitypolicy.Thechargewithintheseaccountsis£3.500||||(2022:|
||£2,979)inrespect ofthispolicy.|||||
|6.|**TA. GIBLE FIXED ASSETS **|**Office furniture**|**Clinical **|||
|||**and equipment **|**equipment **|**Total **||
|||£|£|£||
||**Cost **|||||
||AtIApril2022|6,437|275,327|281,764||
||Additionsinyear|340|||340|
||Disposalsin year|||||
||Asat31March 2023|6,777|275,327|282,I0-+||
||**Depreciation **|||||
||AtIApril2022|6,254|275.327|281,581||
||Charge forthe year|219|||219|
||Eliminated ondisposal|||||
||At31March 2023|6.473|275,327|281.800||
||**Net Book Value **|||||
||At3IMarch 2023|304|||304|
||At31March2022|183|||183|
|7.|**INVESTME~TS **||**2023 **|**2022 **||
||||£|£||
||MarketvalueatIApril2022||1,192.739|l.l93.498||
||Additions|||||
||Disposals|||||
||Cashwithdrawals||(150,000)|||
||Realisedlossonsale|||||
||Unrealised(loss)/profitoninvestments||17,781||(759)|
||Marketvalueat31March2023||1,060.520|l.l92.739||





|**8.**|**DEBTORS **|**`2023`**|**`2022 `**|
|---|---|---|---|
|||£|£|
||Prepaymentsandaccruedincome|17,394|28,919|
||Other debtors|406,009|8.149|
|||423,403|37.068|
|**9. **|**CREDITORS: AMOUNTS FALLING **|**`2023`**|**`2022 `**|
||**DUE IN LESS THAN O1\EYEAR **|£|£|
||Accrualsanddeferredincome|66.108|282.540|
||Othercreditors|7,800|4.306|
|||73,908|286,846|
|**10. **|**UNRESTRICTED FUNDS **|**`2023`**|**`2022 `**|
|||£|£|
||**General **|||
||AtIApril2022|1,139,681|1,351.918|
||(Deficit)forthefinancialyear|(58.432)|(212,237)|
||Al3IMarch 2023|1,081,249|1.139.681|





||Totalfunds|Total|Total|Totalfunds|
|---|---|---|---|---|
||brought|incoming|resources|carried|
||forwardas|resources|expended|forward as at|
||atIApril|||31March|
||2022|||2023|
||£|£|£|£|
|ProstateCancerResearch|212,724|1,500|(36.10I)|178,123|
|SGULOvarian|44,509||(23.559)|20,950|
|ImperialOvarian||7.069||7,069|
|AlbertoClinical||50,000||50,000|
|HelenFeatherTrials||13,655||13,665|
|Generalresearch||400.000|(341.775)|58,225|
|Wai'sResearchLON||125|(125)||
|Pete'sCheckpointBlockade||-14.300|(20,833)|23,-167|
|Totalrestrictedfunds|257,233|516,659|(422,393)|351,499|
|Unrestrictedfunds|1,139,681||(162,543)|1,081,249|
|Totalfunds|1,396,914|620,770|(584,936)|1,432,748|



||Totalfunds|Total|Total|Totalfunds|
|---|---|---|---|---|
||brought|incoming|resources|carried|
||forwardas|resources|expended|forwardasat|
||atIApril|||31March|
||2021|||2022|
||£|£|£|£|
|ProstateCancerResearch|176.432|55,350|(I9.058)|212,724|
|Ovarian|4-1.509|||44,509|
|Pancreatic||15,606|l15.606)||
|SeniorLecturerAssociate|1,2-+3|1,000|(2.243)||
|Generalresearch||401,300|(401,300)||
|Symposium|||||
|Totalrestrictedfunds|222.184|460,938|(438,207)|257,233|
|Unrestrictedfunds|1,351,918|224,094|(305.367)|1,139.681|
|Totalfunds|1,574,102|685,032|(743,574)|1,396,914|






## 

|**l2. **|**A~AL YSIS OF NET ASSETS **|**Unrestricted **|**Restricted **|**Total **|
|---|---|---|---|---|
||**BETWEENFUNDS **|**Funds **|**Funds **||
|||£|£|£|
||**Fund balances at 31 March 2023 are represented by: **||||
||Tangibleassets|304||304|
||Investments|1,060,520||1,060.520|
||Netcurrentassets|20,425|351,499|371.924|
|||1,081,249|351,499|1,432.748|
||**Fund balancesat 31 March 2022 arerepresented by: **||||
||Tangibleassets|180||180|
||Investments|1,192,739||1,192,739|
||Netcurrentliabilities|(53,238)|257,233|203,995|
|||I,139,681|257,233|1,396,914|





|||**Unrestricted **|**Restricted **|**Total **|
|---|---|---|---|---|
|||**Funds **|**Funds **|**Funds**|
|||**2022 **|**2022 **|**2022 **|
||**Notes **|£|£|£|
|**I:\'COME FROM: **|||||
|**Donationsand legacies **||92,610|4 73.256|565,866|
|**Charitableactivities **|||||
|Symposium|||||
|**Investment income **||520||520|
|**Total income **||93,l30|473.256|566,386|
|**EXPENDITURE ON: **|||||
|Raisingfunds||64,l18||64,118|
|Charitableactivities||2-+1.2-+9|438,207|679,456|
|**Total expenditure **|2|305,367|438.207|743,574|
|**Xet income/(expenditure) before investment **|||||
|**(losses) **||(212.237)|35,049|(177.188)|
|et(losses) oninvestments|7||||
|**:\et movementinfunds **||(212,237)|35,049|(177,188)|
|**Balance brought forward **I**April2021 **||1,351.918|222,184|1,574,102|
|**Balance carried forward 31 March 2022 **|IO.II|1,139,681|257,233|1,396,914|